Fibrates Revisited: Potential Role in Cardiovascular Risk Reduction

Nam Hoon Kim, Sin Gon Kim

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Fibrates, peroxisome proliferator-activated receptor-α agonists, are potent lipid-modifying drugs. Their main effects are reduction of triglycerides and increase in high-density lipoprotein levels. Several randomized controlled trials have not demonstrated their benefits on cardiovascular risk reduction, especially as an "add on" to statin therapy. However, subsequent analyses by major clinical trials, meta-analyses, and real-world evidence have proposed their potential in specific patient populations with atherogenic dyslipidemia and metabolic syndrome. Here, we have reviewed and discussed the accumulated data on fibrates to understand their current status in cardiovascular risk management.

Original languageEnglish
Pages (from-to)213-221
Number of pages9
JournalDiabetes and Metabolism Journal
Volume44
Issue number2
DOIs
Publication statusPublished - 2020 Apr 1

Keywords

  • Cardiovascular diseases
  • Dyslipidemias
  • Hydroxymethylglutaryl-CoA reductase inhibitors
  • Metabolic syndrome
  • PPAR alpha
  • Peroxisome proliferator-activated receptors

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism

Fingerprint Dive into the research topics of 'Fibrates Revisited: Potential Role in Cardiovascular Risk Reduction'. Together they form a unique fingerprint.

  • Cite this